Oric Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
ORIC
CUSIP
68622P109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 68622P109 since 12/18/2024, newest first.

Filer % of Class Filed
Venrock Healthcare Capital Partners III, L.P. 13G/A Amendment 2
4.2% 5/15/2026
Event 3/31/2026
Point72 Asset Management, L.P. 13G/A Amendment 1
0% 5/15/2026
Event 3/31/2026
Viking Global Investors LP 13G/A Amendment 3
7.8% 5/15/2026
Event 3/31/2026
Price T Rowe Associates Inc /MD/ 13G 5.4% 5/15/2026
Event 3/31/2026
Pfizer Inc 13G/A Amendment 1 3.3% 5/12/2026
Event 3/31/2026
Venrock Healthcare Capital Partners III, L.P. 13G/A Amendment 1
5.8% 2/17/2026
Event 12/31/2025
BlackRock, Inc. 13G 5.6% 1/21/2026
Event 12/31/2025
Column Group II, LP 13G/A Amendment 3
3.7% 11/17/2025
Event 9/30/2025
Alkeon Capital Management LLC 13G/A Amendment 3
4.6% 11/13/2025
Event 9/30/2025
Nextech Crossover I GP S.a r.l. 13G/A Amendment 2
8.4% 8/14/2025
Event 6/30/2025
SR One Capital Management, LLC 13D/A Amendment 1
4.8% 8/14/2025
Event 8/12/2025
Viking Global Investors LP 13G/A Amendment 2
10.0% 8/14/2025
Event 6/30/2025
EcoR1 Capital, LLC 13G
6.9% 8/5/2025
Event 7/29/2025
BlackRock, Inc. 13G/A Amendment 1 4.2% 7/17/2025
Event 6/30/2025
SR One Capital Management, LLC 13D
5.4% 6/5/2025
Event 5/29/2025
Point72 Asset Management, L.P. 13G
5.1% 6/4/2025
Event 5/29/2025
Venrock Healthcare Capital Partners III, L.P. 13G
7.7% 5/30/2025
Event 4/8/2025
Venrock Healthcare Capital Partners III, L.P. 13G/A Amendment 1
4.5% 5/15/2025
Event 3/31/2025
Frazier Life Sciences Public Fund, L.P. 13G/A Amendment 1
2.0% 5/15/2025
Event 3/31/2025
Viking Global Investors LP 13G/A Amendment 1
9.2% 5/15/2025
Event 3/31/2025
FMR LLC 13G/A Amendment 7
3.5% 2/12/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 7 24.6 k $300 k
2026 Q2 187 124 M $1.41 B
2026 Q1 185 119 M $1.51 B
2025 Q4 169 120 M $980 M
2025 Q3 157 108 M $1.29 B
2025 Q2 148 93.5 M $949 M
2025 Q1 147 79.2 M $442 M
2024 Q4 136 75.8 M $612 M
2024 Q3 126 69.9 M $715 M
2024 Q2 116 68.1 M $482 M
2024 Q1 120 64.6 M $888 M
2023 Q4 99 51.2 M $471 M
2023 Q3 96 49.0 M $297 M
2023 Q2 89 45.5 M $353 M
2023 Q1 76 33.1 M $189 M
2022 Q4 70 32.5 M $193 M
2022 Q3 81 32.7 M $105 M
2022 Q2 88 32.8 M $147 M
2022 Q1 105 34.0 M $182 M
2021 Q4 82 34.9 M $513 M
2021 Q3 83 36.4 M $762 M
2021 Q2 79 36.1 M $639 M
2021 Q1 85 35.7 M $874 M
2020 Q4 77 32.6 M $1.10 B
2020 Q3 56 22.2 M $553 M
2020 Q2 67 21.5 M $722 M